Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

News from ASH 2018—how can we afford innovation in thefuture?

News from ASH 2018—how can we afford innovation in thefuture? editorial memo (2019) 12:189–190 https://doi.org/10.1007/s12254-019-00523-w News from ASH 2018—how can we afford innovation in the future? Dominik Wolf Received: 20 August 2019 / Accepted: 21 August 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2019 The latest data presented at ASH 2018 (and also EHA myeloma as well as various lymphatic diseases. These 2019) document the continuous success in improving data exemplify how intelligent novel targeted treat- the outcome and tolerability of anti-cancer thera- ment approaches can be applied, which are—even pies and the management of coagulation disorders though larger and particularly randomized trial data in hematology. Important topics are summarized in are eagerly awaited—already showing dramatic im- short reviews in this issue of MEMO [1–4]. Exemplar- provement of the prognosis of relapsed/refractory ily, the integration of oral BTK and BCL-2 inhibitors lymphoma patients and considerable activity also into the first-line management of chronic lympho- in late-line myeloma treatment. It is tempting to cytic leukemia (CLL) highlights the evolvement from speculate that more potent and fine-tunable CAR- classic chemo-immunotherapy to more targeted ap- TC technology platforms (e.g., SUPRA-CAR T cells), proaches using oral compounds guaranteeing better their earlier use and/or the combination of these tar- tolerability as well http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

News from ASH 2018—how can we afford innovation in thefuture?

Loading next page...
 
/lp/springer-journals/news-from-ash-2018-how-can-we-afford-innovation-in-thefuture-ewU1DpbVJf

References (4)

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-019-00523-w
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2019) 12:189–190 https://doi.org/10.1007/s12254-019-00523-w News from ASH 2018—how can we afford innovation in the future? Dominik Wolf Received: 20 August 2019 / Accepted: 21 August 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2019 The latest data presented at ASH 2018 (and also EHA myeloma as well as various lymphatic diseases. These 2019) document the continuous success in improving data exemplify how intelligent novel targeted treat- the outcome and tolerability of anti-cancer thera- ment approaches can be applied, which are—even pies and the management of coagulation disorders though larger and particularly randomized trial data in hematology. Important topics are summarized in are eagerly awaited—already showing dramatic im- short reviews in this issue of MEMO [1–4]. Exemplar- provement of the prognosis of relapsed/refractory ily, the integration of oral BTK and BCL-2 inhibitors lymphoma patients and considerable activity also into the first-line management of chronic lympho- in late-line myeloma treatment. It is tempting to cytic leukemia (CLL) highlights the evolvement from speculate that more potent and fine-tunable CAR- classic chemo-immunotherapy to more targeted ap- TC technology platforms (e.g., SUPRA-CAR T cells), proaches using oral compounds guaranteeing better their earlier use and/or the combination of these tar- tolerability as well

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 26, 2019

There are no references for this article.